• Something wrong with this record ?

Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation

P. Vaňhara, E. Lincovaá A. Kozubík, P. Jurdic, K. Souček, J. Šmarda

. 2009 ; 78 (4) : 213-222.

Language English Country Great Britain

Document type Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12008551

Grant support
NS9875 MZ0 CEP Register

Survival and capability of cancer cells to form metastases fundamentally depend on interactions with their microenvironment. Secondary tumors originating from prostate carcinomas affect remodeling of bone tissue and can induce both osteolytic and osteocondensing lesions. However, particular molecular mechanisms responsible for selective homing and activity of cancer cells in bone microenvironment have not been clarified yet. Growth/differentiation factor-15 (GDF-15), a distant member of the TGF-beta protein family, has recently been associated with many human cancers, including prostate. We show that both pure GDF-15 and the GDF-15-containing growth medium of 1,25(OH)(2)-vitamin D(3)-treated prostate adenocarcinoma LNCaP cells suppress formation of mature osteoclasts differentiated from RAW264.7 macrophages and bone-marrow precursors by M-CSF/RANKL in a dose-dependent manner. GDF-15 inhibits expression of c-Fos and activity of NFkappaB by delayed degradation of IkappaB. Moreover, GDF-15 inhibits expression of carbonic anhydrase II and cathepsin K, key osteoclast enzymes, and induces changes in SMAD and p38 signaling. The lack of functional osteoclasts can contribute to accumulation of bone matrix by reduction of bone resorption. These results unveil new role of GDF-15 in modulation of osteoclast differentiation and possibly in therapy of bone metastases.

000      
03665naa a2200589 a 4500
001      
bmc12008551
003      
CZ-PrNML
005      
20140814120720.0
008      
120316s2009 xxk eng||
009      
AR
040    __
$a ABA008 $b cze $d ABA008
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vaňhara, Petr, $d 1980- $7 xx0106079 $u Department of Experimental Biology, Faculty of Science, Masaryk University
245    10
$a Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation $c P. Vaňhara, E. Lincovaá A. Kozubík, P. Jurdic, K. Souček, J. Šmarda
520    9_
$a Survival and capability of cancer cells to form metastases fundamentally depend on interactions with their microenvironment. Secondary tumors originating from prostate carcinomas affect remodeling of bone tissue and can induce both osteolytic and osteocondensing lesions. However, particular molecular mechanisms responsible for selective homing and activity of cancer cells in bone microenvironment have not been clarified yet. Growth/differentiation factor-15 (GDF-15), a distant member of the TGF-beta protein family, has recently been associated with many human cancers, including prostate. We show that both pure GDF-15 and the GDF-15-containing growth medium of 1,25(OH)(2)-vitamin D(3)-treated prostate adenocarcinoma LNCaP cells suppress formation of mature osteoclasts differentiated from RAW264.7 macrophages and bone-marrow precursors by M-CSF/RANKL in a dose-dependent manner. GDF-15 inhibits expression of c-Fos and activity of NFkappaB by delayed degradation of IkappaB. Moreover, GDF-15 inhibits expression of carbonic anhydrase II and cathepsin K, key osteoclast enzymes, and induces changes in SMAD and p38 signaling. The lack of functional osteoclasts can contribute to accumulation of bone matrix by reduction of bone resorption. These results unveil new role of GDF-15 in modulation of osteoclast differentiation and possibly in therapy of bone metastases.
590    __
$a bohemika - dle Pubmed
650    02
$a kyselá fosfatasa $x metabolismus $7 D000135
650    02
$a zvířata $7 D000818
650    02
$a kalcitriol $x farmakologie $7 D002117
650    02
$a karboanhydrasa II $x antagonisté a inhibitory $7 D024402
650    02
$a kathepsin K $x antagonisté a inhibitory $x genetika $7 D056657
650    02
$a buněčná diferenciace $x účinky léků $7 D002454
650    02
$a buněčné linie $7 D002460
650    02
$a nádorové buněčné linie $7 D045744
650    02
$a kultivační média speciální $x farmakologie $7 D017077
650    02
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    02
$a femur $x cytologie $7 D005269
650    02
$a růstový diferenciační faktor 15 $x farmakologie $7 D055436
650    02
$a lidé $7 D006801
650    02
$a izoenzymy $x metabolismus $7 D007527
650    02
$a faktor stimulující kolonie makrofágů $x farmakologie $7 D016173
650    02
$a makrofágy $x cytologie $7 D008264
650    02
$a mužské pohlaví $7 D008297
650    02
$a myši $7 D051379
650    02
$a inbrední kmeny myší $7 D008815
650    02
$a NF-kappa B $x antagonisté a inhibitory $7 D016328
650    02
$a osteoklasty $x metabolismus $x účinky léků $7 D010010
650    02
$a nádory prostaty $x metabolismus $7 D011471
650    02
$a protoonkogenní proteiny c-fos $x antagonisté a inhibitory $7 D016760
650    02
$a ligand RANK $x farmakologie $7 D053245
650    02
$a časové faktory $7 D013997
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Slabáková, Eva $7 xx0125840
700    1_
$a Kozubík, Alois, $d 1958- $7 mzk2004237023
700    1_
$a Jurdic, Pierre
700    1_
$a Souček, Karel $7 xx0140754
700    1_
$a Šmarda, Jan, $d 1961- $7 mzk2006343362
773    0_
$t Differentiation $p Differentiation $g Roč. 78, č. 4 (2009), s. 213-222 $w MED00001406 $x 0143-2044
773    0_
$p Differentiation $g 78(4):213-22, 2009 Nov
910    __
$a ABA008 $b x $y 4 $z 0
990    __
$a 20120319124514 $b ABA008
991    __
$a 20140814121049 $b ABA008
999    __
$a ok $b bmc $g 901917 $s 765446
BAS    __
$a 3
BMC    __
$a 2009 $b 78 $c 4 $d 213-222 $m Differentiation $x MED00001406
GRA    __
$a NS9875 $p MZ0
LZP    __
$a 2012-1Q10/jj

Find record